Provided by Tiger Trade Technology Pte. Ltd.

Oncolytics Biotech Inc

1.06
-0.0400-3.64%
Post-market: 1.060.00000.00%19:56 EDT
Volume:708.39K
Turnover:766.01K
Market Cap:123.10M
PE:-3.53
High:1.10
Open:1.10
Low:1.06
Close:1.10
52wk High:1.51
52wk Low:0.3258
Shares:116.13M
Float Shares:114.00M
Volume Ratio:0.45
T/O Rate:0.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3000
EPS(LYR):-0.3000
ROE:-10187.64%
ROA:-170.96%
PB:-32.40
PE(LYR):-3.53

Loading ...

Company Profile

Company Name:
Oncolytics Biotech Inc
Exchange:
NASDAQ
Establishment Date:
1998
Employees:
29
Office Location:
322 11th Avenue SW,Suite 804,Calgary,Alberta,Canada
Zip Code:
T2R 0C5
Fax:
403 283 0858
Introduction:
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Directors

Name
Position
Jared Kelly
Chief Executive Officer and Director
Angela Holtham
Independent Director
Bernd R. Seizinger
Independent Director
Deborah M. Brown
Independent Director
James T. Parsons
Independent Director
Jonathan Rigby
Independent Director
Patricia Andrews
Independent Director
Wayne Pisano
Chair and Independent Director

Shareholders

Name
Position
Jared Kelly
Chief Executive Officer and Director
Kirk J. Look
Chief Financial Officer
Allison Hagerman
Chief Technology Officer
Andrew Aromando
Chief Business Officer
Thomas C. Heineman
Chief Medical Officer